Two Options the sweetest among them is bitter: Fournier-gangrene associated with sodium-glucose co-transporter 2-inhibitors
暂无分享,去创建一个
[1] C. Kortepeter,et al. Fournier Gangrene Associated With SodiumGlucose Cotransporter-2 Inhibitors , 2019, Annals of Internal Medicine.
[2] I. Shergill,et al. Fournier’s gangrene and its emergency management , 2006, Postgraduate Medical Journal.
[3] Kira B. Harris,et al. The Clinical Efficacy and Safety of Sodium Glucose Cotransporter‐2 Inhibitors in Adults with Type 2 Diabetes Mellitus , 2013, Pharmacotherapy.
[4] Mathew D. Sorensen,et al. Fournier's Gangrene: population based epidemiology and outcomes. , 2009, The Journal of urology.
[5] K. Johnsson,et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.
[6] B. Voelzke,et al. Presentation and Diagnosis of Fournier Gangrene. , 2017, Urology.
[7] K. Hureibi,et al. The development of Fournier's gangrene following rubber band ligation of haemorrhoids , 2013, BMJ Case Reports.
[8] P. Dasgupta,et al. Fournier's gangrene. A clinical review. , 2016, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[9] N. Eke,et al. Fournier's gangrene: a review of 1726 cases , 2000, The British journal of surgery.
[10] I. Thompson,et al. Impact of diabetes mellitus on the presentation and outcomes of Fournier's gangrene. , 2002, Urology.
[11] N. Tatonetti,et al. Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS) , 2014, Drug Safety.
[12] P. Norman,et al. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study , 2015, Cardiovascular Diabetology.
[13] P. Riegels-Nielsen,et al. [Fournier's gangrene]. , 1984, Ugeskrift for laeger.
[14] L. Geiss,et al. Declining Rates of Hospitalization for Nontraumatic Lower-Extremity Amputation in the Diabetic Population Aged 40 Years or Older: U.S., 1988–2008 , 2012, Diabetes Care.
[15] Olga Hilas,et al. Canagliflozin (invokana), a novel oral agent for type-2 diabetes. , 2013, P & T : a peer-reviewed journal for formulary management.